Compare AbbVie Inc (ABBV) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Palantir Technologies Inc — how do they compare? AbbVie Inc trades at $253.82 (market cap $449.91B), while Palantir Technologies Inc trades at $130.64 (market cap $322.13B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays a 2.72% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| ABBV | PLTR | |
|---|---|---|
Market Cap | $449.91B | $322.13B |
Sector | Health | Technology |
52-Week High | $261.07 | $207.18 |
52-Week Low | $184.85 | $107.27 |
Enterprise Value | $513.38B | $314.31B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
PLTR trades at $134.37, up 4.03% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $4.48B in 2025, with net income reaching $1.63B, though valuation ratios remain elevated. Recent news highlights AI partnerships with Nvidia and expansion in Mexico, driving positive sentiment.
Outlook is positive given robust earnings growth and AI adoption, but high P/E of 148.92 poses valuation risk. Analyst consensus price target is $185.67, with 46% buy ratings. Key risks include competitive pressures and reliance on government contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
